- List
- By Topic
- On Map
- Search Details

17167137 [PUBMED-IDS]
Need help? See RSS Feeds
Choose a feed type:

17167137 [PUBMED-IDS] (10 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03240549 | Not yet recruiting | Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease |
|
|
Interventional | Phase 2 |
|
Other |
|
|
159 | All | 18 Years to 75 Years (Adult, Senior) | NCT03240549 | 121-2016007 | August 2017 | August 31, 2018 | September 30, 2019 | August 7, 2017 | August 7, 2017 | |||
2 | NCT00021060 | Completed | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer |
|
|
Interventional | Phase 2 Phase 3 |
|
NIH |
|
|
842 | All | 18 Years and older (Adult, Senior) | NCT00021060 | NCI-2012-02947 E4599 U10CA021115 CDR0000068744 |
August 2002 | September 2006 | January 27, 2003 | February 27, 2013 |
|
|||
3 | NCT00424840 | Completed | Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
19 | All | 18 Years and older (Adult, Senior) | NCT00424840 | UM200601 | June 2006 | March 2014 | March 2014 | January 22, 2007 | November 19, 2014 |
|
||
4 | NCT02316327 | Completed | Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab |
|
|
Interventional | Phase 4 |
|
Other |
|
|
19 | All | 18 Years and older (Adult, Senior) | NCT02316327 | IMPACT 2012-000459-15 |
July 2013 | September 2016 | October 2016 | December 12, 2014 | October 5, 2016 |
|
||
5 | NCT00653939 | Completed Has Results |
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
63 | All | 18 Years and older (Adult, Senior) | NCT00653939 | OXC401-216 | FALCON | March 2008 | July 2011 | October 2011 | April 7, 2008 | February 9, 2015 | February 9, 2015 |
|
6 | NCT02591615 | Recruiting | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
90 | All | 18 Years and older (Adult, Senior) | NCT02591615 | AFT-09 | March 2016 | April 2019 | December 2019 | October 29, 2015 | April 13, 2018 |
|
||
7 | NCT03447678 | Not yet recruiting | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. |
|
|
Interventional | Phase 2 |
|
Other |
|
|
65 | All | 18 Years and older (Adult, Senior) | NCT03447678 | INT 178-17 | PEOPLE | March 1, 2018 | March 1, 2021 | March 1, 2021 | February 27, 2018 | February 28, 2018 |
|
|
8 | NCT02577341 | Recruiting | Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
150 | All | 18 Years to 70 Years (Adult, Senior) | NCT02577341 | 2014-FXY-061 | August 2015 | July 2020 | July 2020 | October 16, 2015 | April 18, 2017 |
|
||
9 | NCT01660399 | Unknown † | Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy |
|
|
Interventional | Phase 2 |
|
Other |
|
|
300 | All | 18 Years and older (Adult, Senior) | NCT01660399 | CIH-CHP-201205001 | August 2012 | November 2016 | December 2016 | August 8, 2012 | December 22, 2015 |
|
||
10 | NCT00908219 | Withdrawn | A Study of Bevacizumab to Prevent Malignant Ascites |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
0 | All | 18 Years and older (Adult, Senior) | NCT00908219 | H-21728 AVF4534s |
July 2009 | February 2011 | February 2011 | May 25, 2009 | June 3, 2015 |
|
† Study has passed its completion date and status has not been verified in more than two years.